Furthermore, despite the dual role of EZH2 in initiating and maintaining the disease, evidence consistently suggests that EZH2 is functionally required for full-blown AML, thus making it an attractive therapeutic target. This evidence concerns the gene EZH2 and acute myeloid leukemia.